Similarly, applying retatrutide concentrations to semaglutide would create volumes so small they are nearly impossible to measure
, - 2 , 2018 2-3- (ADA 2018
This is likely associated with rapid weight loss rather than a direct medication effect, representing a condition called telogen effluvium
In UK practice, those are regulatory and patient-safety questions first, and treatment questions second
With the expected growing number of GLP-1 users, this could have a potential impact of USD 55-90 bn on grocery spending in the US in 2030
Another study published by Diabetes, Obesity & Metabolism in June 2025 further supported this link, concluding that the five-year risk of developing NAION doubled in patients using GLP-1 drugs compared to non-users